The global immunoglobulins market is expected to grow rapidly due to the rise in the incidence of autoimmune illnesses,. According to the Immune Deficiency Foundation (IDF), primary immunodeficiency affected 83 out of every 100,000 people in North America in 2017, resulting in 350 hereditary disorders. As the world's geriatric population grows, so does the demand for more effective immunological therapies.
